Switzerland-based Polyphor Ltd. is planning to file for an IPO in the second quarter of 2018, Reuters reported, citing anonymous sources.
The Swiss company is looking to raise more than CHF 100 million in the IPO to advance its pipeline. It could have a value of about CHF 500 million after it goes public, according to one of Reuters' sources.
Polyphor is working with UBS and Deutsche Bank for the transaction, Reuters reported.
Polyphor is a specialty pharmaceutical company focused on developing macrocycle drugs to address antibiotic resistance and severe respiratory diseases. Its lead drug candidate, Murepavadin, is being studied in a phase 3 study as a potential treatment for nosocomial pneumonia caused by the pseudomonas aeruginosa bacteria.
